Open AccessHigh Mortality Associated with Retreatment of Tuberculosis in a Clinic in Kampala, Uganda: A Retrospective Study
Author(s) -
Carlos Acuña-Villaorduña,
Irene Ayakaka,
Scott DrydenPeterson,
Susan Nakubulwa,
William Worodria,
Nancy Reilly,
Jennifer Hosford,
Kevin P. Fennelly,
Alphonse Okwera,
Edward C. JonesLópez
Publication year - 2015
Publication title -
american journal of tropical medicine and hygiene
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.015
H-Index - 151
eISSN - 1476-1645
pISSN - 0002-9637
DOI - 10.4269/ajtmh.14-0810
Subject(s) - ethambutol , pyrazinamide , medicine , rifampicin , tuberculosis , regimen , isoniazid , leprosy , streptomycin , surgery , pediatrics , family medicine , antibiotics , immunology , pathology , microbiology and biotechnology , biology
The World Health Organization recommends for tuberculosis retreatment a regimen of isoniazid (H), rifampicin (R), ethambutol (E), pyrazinamide (Z), and streptomycin (S) for 2 months, followed by H, R, E, and Z for 1 month and H, R, and E for 5 months. Using data from the National Tuberculosis and Leprosy Program registry, this study determined the long-term outcome under programmatic conditions of patients who were prescribed the retreatment regimen in Kampala, Uganda, between 1997 and 2003. Patients were traced to determine their vital status; 62% (234/377) patients were found dead. Having ≤ 2 treatment courses and not completing retreatment were associated with mortality in adjusted analyses.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom